Adaptimmune Therapeutics (Nasdaq: ADAP) saw its shares close down more than 10% at $1.16, after it disclosed that Roche (ROG: SIX) subsidiary Genentech has terminated their strategic collaboration entered into in 2021.,
The deal was based on the commercialization of allogeneic T-cell therapies based on ADAP's induced pluripotent stem cell (iPSC) derived allogeneic platform, with a focus on afamitresgene autoleucel (afami-cel).
Adaptimmune said it remains focused on launching afami-cel later this year with a US Food and Drug Administration (FDA) action date of August 4 and developing its broader sarcoma franchise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze